Voyager Therapeutics (VYGR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising advancement of Voyager Therapeutics’ VY7523 program. The initial safety data from the Phase 1 single ascending dose trial in healthy volunteers showed that VY7523 met all primary and secondary endpoints, demonstrating safety, tolerability, and dose-proportional pharmacokinetics. This positive outcome supports the progression to a Phase 1b multiple ascending dose trial in patients with early onset Alzheimer’s Disease, which is expected to provide crucial tau PET imaging data by the second half of 2026.
Moreover, preclinical data indicating a significant reduction in the spread of pathological tau further strengthens the potential of VY7523 to make a notable impact in the Alzheimer’s treatment landscape. Additionally, the anticipation of data from competitor programs and recent positive results from similar tau-targeting therapies bolster the outlook for VY7523. These factors, combined with a valuation approach that considers the potential success of Voyager’s assets and a calculated price target of $30 per share, underpin Trucchio’s Buy rating for Voyager Therapeutics.
Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Sangamo Biosciences, and Arrowhead Pharmaceuticals. According to TipRanks, Trucchio has an average return of -3.2% and a 31.13% success rate on recommended stocks.